While the best 3D printers on the market for consumers have certainly evolved to become much more capable, they’re still not match for what’s available to industrial and medical organizations. As an example, take ROKIT’s latest offering – a new 3D bioprinter for tissue engineering research.
What ROKIT Has Up Its Collective Sleeve
Chances are good that you’ve at least heard of ROKIT. After all, they’re the largest 3D printer manufacturer in South Korea, and their products are used around the world.
They’ve created consumer-facing printers, industrial printers, commercial printers and more. Now, they’re turning their sights on the medical research community with the debut of the Edison Invivo 3D bioprinter.
The Edison Invivo is the first fruit of a $3 million grant from the South Korean government to ROKIT in 2015 for the purpose of exploring bioprinting with 3D technology. It won’t be the last thing the company develops, but it’s well worth taking a look at.
According to company officials, the Edison Invivo manages to overcome a lot of hurdles to 3D printing tissue. They state that, “It can grow cells in three-dimensional structures that become transplantable tissues.
These personalized transplants without side effects, such as immune rejection, are possible because they can be transplanted into autologous cells collected from the patient’s own body.”
With that being said, the Edison Invivo isn’t the only 3D bioprinter on the market. There are quite a few others out there, many of which offer similar functionality.
However, the South Korean company believes that their 3D printer manages to top those other contenders. One way they’re reshaping the industry is by offering higher performance and better reliability, but with a lower price tag.
“Despite the increase in demand for 3D printing three-dimensional tissue engineering research, the prices of existing products are too high. In many cases, 3D bioprinters focus on simple mechanical efficiency rather than specifications that researchers want.”
It sounds like they’re making a case for the Edison Invivo being lower priced, while offering more features, but the company has yet to announce pricing or availability.
They did go into greater detail about what their printer can do, though. For instance, it can use a number of different bio inks that aren’t compatible with other printers.
It can also use a number of other materials, including PLLA, collagen, PLGA and several others. By providing compatibility with a wider range of materials, the manufacturer hops to take the lead in a burgeoning industry.
“Based on the experience as former CEO of Celltrion Healthcare, we developed the Edison Invivo by merging the bio and 3D print technology,” explained the company’s CEO, Seok Hwan You.
While pricing and availability have yet to be announced, it sounds like the new bioprinter will definitely be a game changer for the industry.